MyOme Launches Free Genetic Testing Program for ADH1 Families
Event summary
- MyOme launched CASRcade, a no-charge family cascade genetic testing program for U.S. families affected by Autosomal Dominant Hypocalcemia Type 1 (ADH1).
- The program offers free familial variant testing (FVT) and genetic counseling for biological relatives up to fourth degree of confirmed ADH1 patients.
- Sponsored by BridgeBio, CASRcade aims to identify relatives carrying the CASR gene variant associated with ADH1 for earlier diagnosis and care.
- MyOme will perform targeted genetic sequencing and facilitate access to genetic counseling for positive results.
The big picture
MyOme's CASRcade program addresses a critical gap in genetic testing for rare diseases, leveraging its whole-genome analysis platform to provide actionable insights. The initiative aligns with broader trends in preventive healthcare and the growing emphasis on family-based genetic screening. The partnership with BridgeBio underscores the strategic importance of collaborative efforts in advancing rare disease diagnostics.
What we're watching
- Program Adoption
- How quickly healthcare providers and families will enroll in the CASRcade program, given the no-charge model.
- Diagnostic Impact
- Whether the program will significantly increase early diagnoses of ADH1 among at-risk relatives.
- Strategic Partnerships
- The potential for BridgeBio to expand its collaboration with MyOme beyond this program.
Related topics
